Inspire Medical: Golden Opportunity To Monetize A Fundamentally Mispriced Selloff

The key dislocation is that the market is likely pricing the revenue inflection as if it were demand destruction, when it is more plausibly a billing/reimbursement air pocket. That matters because a temporary coding/CMS friction event can compress reported growth for 1-2 quarters without meaningfully impairing the installed base, and those periods often create the best entry points for high-gross-margin medtech names with recurring utilization. The balance-sheet asymmetry is unusually strong here: with no debt and ample liquidity, INSP can keep investing through the trough while weaker competitors have to defend cash flow.

Second-order competitive effects may actually favor INSP. If payer scrutiny and reimbursement complexity rise, smaller or less capitalized entrants are forced to spend more on market access and evidence generation, which slows share gains even if their clinical pitch is intact. On the other side, GLP-1 penetration is more likely to expand the diagnosable and treatable sleep-apnea population than cannibalize it near term, because weight-loss therapy can surface persistent residual OSA patients who still need device therapy; that creates a longer-duration conversion funnel rather than an immediate substitution threat.

The main risk is timing, not thesis. If CMS disruption lasts beyond one additional reimbursement cycle, the market will start extrapolating a structural demand problem and the multiple could overshoot to the downside before fundamentals normalize. The other tail risk is litigation or policy headlines giving shorts a narrative anchor; in that scenario, price action can remain weak for months even if underlying procedure volumes recover later. For NYXH, the bar to matter is a lot higher: they need either a reimbursement win or a sustained clinical differentiation catalyst, otherwise they remain a financing-sensitive follower in a crowded market.

The contrarian view is that consensus may be underestimating the convexity of a normalization trade. If reported revenue re-accelerates over the next 1-2 quarters, the stock can re-rate quickly because depressed multiples on temporary fear usually unwind faster than operating estimates do. The opportunity set is therefore less about owning a clean secular compounder and more about exploiting a mispriced bridge period between billing noise and underlying demand.